Skip to content

Study · Randomized controlled trial · 2019

2 results

Neural correlates of liraglutide effects in persons at risk for Alzheimer's disease.

Watson KT, Wroolie TE, Tong G, Foland-Ross LC, Frangou S, Singh M, McIntyre RS, Roat-Shumway S, Myoraku A, Reiss AL, Rasgon NL

Behavioural brain research9 Aug 2018Cited by 118 (Europe PMC)

PMID30099030 (opens in a new tab)DOI10.1016/j.bbr.2018.08.006 (opens in a new tab)PepBankPUB-30099030
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cognitively normal late middle-aged adults with subjective cognitive complaints, 12 weeks of liraglutide significantly improved intrinsic connectivity within the default mode network relative to placebo.

    In plain wordsIn middle-aged adults with memory worries, liraglutide improved brain network connectivity more than placebo after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    IncreaseDefault mode network intrinsic connectivity
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    At time point 2, we observed significant improvement in intrinsic connectivity within the default mode network (DMN) in the active group relative to placebo.
    2 context sentences
    Summary · context
    The purpose of this double-blinded, placebo-controlled study was to examine the neural effects of administration of liraglutide in cognitively normal late middle-aged individuals with subjective cognitive complaints (half of subjects had family history of AD).
    Summary · context
    Seed-based resting state connectivity using functional magnetic resonance imaging (fMRI) was conducted before and after 12 weeks of liraglutide treatment or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cognitively normal late middle-aged adults with subjective cognitive complaints, no cognitive differences were detected between liraglutide and placebo groups after 12 weeks.

    In plain wordsIn middle-aged adults with memory worries, thinking test results did not differ between liraglutide and placebo after 12 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeCognitive performance
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were no detectable cognitive differences between study groups after this duration of treatment.
    2 context sentences
    Summary · context
    The purpose of this double-blinded, placebo-controlled study was to examine the neural effects of administration of liraglutide in cognitively normal late middle-aged individuals with subjective cognitive complaints (half of subjects had family history of AD).
    Summary · context
    Seed-based resting state connectivity using functional magnetic resonance imaging (fMRI) was conducted before and after 12 weeks of liraglutide treatment or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.